Literature DB >> 6293980

Complement components, C1 activation and disease activity in SLE.

G Sturfelt, A G Sjöholm, B Svensson.   

Abstract

Laboratory parameters were studied in 8 systemic lupus erythematosus patients during periods of high and low disease activity, mainly as defined by clinical criteria. Renal manifestations were present in 6 patients 5 of which showed antibodies to native DNA. C-reactive protein was raised in 3 patients. Only 1 of these showed a superimposed bacterial infection. Markedly high concentrations of C1r-C1s-C1 inactivator cOmplexes (C1r-C1s-Cl IA) in the sera provided direct evidence of C1 activation independent of disease activity. During active disease. C1r-C1s-C1 IA were correlated with C1q binding immune complexes as measured by solid phase, but not by fluid phase assay. Immunochemical concentrations of C1q, C4 and C3 and functional C2 were decreased in active SLE, consistent with sequential activation of the classical pathway. Discrepancies were noted between functional and immunochemical assay for C2 but not for factor B. Although essentially within the normal range, the levels of C1s, C4 binding protein, C5 and properdin were lower during active than during inactive disease. The concentrations of the factors B, I and H did not suggest involvement of the alternative pathway. 1 exceptional patient showed low factor B, a relative decrease of factor I and the presence of Bb fragments in plasma during active SLE. Markedly high factor D values were found. This could partly be explained by reduced renal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6293980     DOI: 10.1159/000233266

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  6 in total

Review 1.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

2.  Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease.

Authors:  A P Weetman; S B Cohen; D A Oleesky; B P Morgan
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

3.  Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions.

Authors:  D A Oleesky; R H Daniels; B D Williams; N Amos; B P Morgan
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

4.  Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.

Authors:  Anders Carlsson; Dirk M Wuttge; Johan Ingvarsson; Anders A Bengtsson; Gunnar Sturfelt; Carl A K Borrebaeck; Christer Wingren
Journal:  Mol Cell Proteomics       Date:  2011-02-24       Impact factor: 5.911

5.  Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.

Authors:  Z Chen; S B Koralov; G Kelsoe
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

Review 6.  Complement as a Therapeutic Target in Systemic Autoimmune Diseases.

Authors:  María Galindo-Izquierdo; José Luis Pablos Alvarez
Journal:  Cells       Date:  2021-01-13       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.